Key result
In morbidly obese patients, DOACs were associated with similar rates of stroke or systemic embolic events compared to warfarin (12.2% vs 11.1%; OR 1.11, 95% CI 0.45-2.78; p=0.82).
Why the study?
Clinical data evaluating anticoagulation with direct oral anticoagulants in morbidly obese patients were limited.
Do direct oral anticoagulants (DOACs) prevent stroke or systemic embolic events as effectively as warfarin in morbidly obese patients?
Cohort (n=180)
No
Do direct oral anticoagulants (DOACs) prevent stroke or systemic embolic events as effectively as warfarin in morbidly obese patients?
Odds Ratio: 1.11 (95% CI 0.45–2.78)
Absolute Event Rate: 12.2% vs 11.1%
p-value: p=0.82
DOACs appear to be a safe and effective alternative to warfarin for the prevention of stroke and systemic embolic events in morbidly obese patients.
No takes yet. Share an insight, caveat, or question.
Similar event rates support considering DOACs in morbid obesity; hypothesis-generating and should not yet change practice.
Kalani et al. (2019) conducted a cohort in Morbid obesity requiring anticoagulation (n=180). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Stroke and systemic embolic events (OR 1.11, 95% CI 0.45-2.78, p=0.82). In morbidly obese patients, DOACs were associated with similar rates of stroke or systemic embolic events compared to warfarin (12.2% vs 11.1%; OR 1.11, 95% CI 0.45-2.78; p=0.82).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: